Correlation of circulating tumor cells (CTCs) with peripheral blood leukocytes to predict outcome in metastatic breast cancer (MBC).

Ugo De Giorgi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), James M. Reuben(The University of Texas MD Anderson Cancer Center), Michal Mego(Comenius University Bratislava), Mario Giuliano(Regione Campania), Vicente Valero(The University of Texas MD Anderson Cancer Center), Naoto T. Ueno(Breast Cancer Care), Antonio Giordano(Harvard University), Emanuela Scarpi(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Ricardo H. Álvarez(The University of Texas MD Anderson Cancer Center), Massimo Cristofanilli(Cornell University)
Journal of Clinical Oncology
May 20, 2016
10.1200/jco.2016.34.15_suppl.11532
Cited by 2

Related Papers

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k